Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study

• Status: Completed
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate topical treatment with Veregen™ 15% ointment as a single therapeutic agent and compare it to combination therapy with Veregen ™ 15% ointment and a single destructive treatment by cryotherapy for non-facial verruca vulgaris in the pediatric population. This novel treatment modality may be useful in the pediatric dermatology community offering a less invasive, painless option for treatment of non-facial verruca vulgaris.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Texas Southwestern Medical Center

Criteria

Inclusion Criteria:

• Male or female of any ethnic background

• Age between 6 years old and 16 years old

• A clinical diagnosis of non-facial verruca vulgaris

• Able to adhere to study visit schedule, Veregen ™ treatment requirements, and baseline cryotherapy treatment in half of patients

• Verruca size greater than 5 mm

Exclusion Criteria:

• Medically unstable patients

• Patients with immunosuppression

• Families who decline participation

• Verruca may not have been treated in preceding 4 weeks prior to enrollment

• Verruca may not be located on the face or genitalia

• Verruca size less than 5 mm